PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases
Open accessThe DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.
Abstract
Cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), result from an impairment of bile flow that leads to the hepatic retention of bile acids, causing liver injury. Until recently, the only approved treatments for PBC were ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). While these therapies slow the progression of PBC in the early stage of the disease, approximately 40% of patients respond incompletely to UDCA, and advanced cases do not respond. UDCA does not improve survival in patients with PSC, and patients often have dose-limiting pruritus reactions to OCA. Left untreated, these diseases can progress to fibrosis and cirrhosis, resulting in liver failure and the need for transplantation. These shortcomings emphasize the urgent need for alternative treatment strategies. Recently, nuclear hormone receptors have been explored as pharmacological targets for adjunct therapy because they regulate enzymes involved in bile acid metabolism and detoxification. In particular, the peroxisome proliferator-activated receptor (PPAR) has emerged as a therapeutic target for patients with PBC or PSC who experience an incomplete response to UDCA. PPARα is predominantly expressed in the liver, and it plays an essential role in the regulation of cytochrome P450 (CYP) and uridine 5’-diphospho-glucuronosyltransferase (UGT) enzymes, both of which are critical enzyme families involved in the regulation of bile acid metabolism and glucuronidation, respectively. Importantly, PPARα agonists, e.g., fenofibrate, have shown therapeutic benefits in reducing elevated markers of cholestasis in patients with PBC and PSC, and elafibranor, the first PPAR (dual α, β/δ) agonist, has been FDA-approved for the second-line treatment of PBC. Additionally, newer PPAR agonists that target various PPAR isoforms (β/δ, γ) are under development as an adjunct therapy for PBC or PSC, although their impact on glucuronidation pathways are less characterized. This review will focus on PPAR-mediated bile acid glucuronidation as a therapeutic pathway to improve outcomes for patients with PBC and PSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Combination treatment with UDCA and fenofibrate alters the concentration and composition of -3/6 bile acid glucuronides during cholestatic liver diseases. Serum was collected from patients treated with either UDCA monotherapy (13–15 mg/kg/day)—“mono”—or combination treatment with UDCA and fenofibrate (145–160 mg/day)—“combo”. Serum bile acid glucuronide concentrations were measured using LC-MS/MS methodology. Data represent the total concentration of -3 and -6 bile acid glucuronides within each patient cohort [18]. PBC (n = 16 “mono”, n = 16 “combo”) and PSC (n = 11 “mono”, n = 12 “combo”). UDCA: ursodeoxycholic acid; PBC: primary biliary cholangitis; PSC: primary sclerosing cholangitis; LCA: lithocholic acid; DCA: deoxycholic acid; HCA: hyocholic acid; HDCA: hyodeoxycholic acid; CDCA: chenodeoxycholic acid.](https://figures.cochat.ai/paper-figures/a50280b894564336bf7395b4aa22c363/ppar-mediated-bile-acid-glucuronidation-therapeutic-targets-for-the-treatment-of-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fibrates including, fenofibrate, gemfibrozil, and bezafibrate, act through activating peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor involved in lipid metabolism and inflammation [33].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“PPAR-α activation enhances bile acid metabolism and secretion [33,34].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086 · cited 1×
“PPAR is an important regulator of several genes involved in bile acid synthesis and metabolism [9].”
BackgroundKliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., & Evans, R. M. (1992) · Nature · doi:10.1038/358771a0 · Cited by 1,741 · cited 1×
“PPREs are characterized by direct repeats of AGGTCA spaced by one nucleotide [10].”
BackgroundA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 1×
“Obeticholic acid (OCA) is also FDA-approved for the treatment of PBC; however, its anti-cholestatic effect is modest and pruritus is a limiting side effect [5].”
BackgroundBile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935 · cited 1×
“Furthermore, most bile acids in humans can also be conjugated to glycine and taurine, at a ~3:1 ratio [34].”
BackgroundA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642 · cited 2×
“Importantly, adjunct therapy with fibrates, e.g., fenofibrate and bezafibrate (pan-PPAR agonist; not FDA-approved), improves biochemical markers of cholestasis, including reducing elevated serum alkaline phosphatase (ALP) and reducing the toxicity of the bile acid pool in PBC and PSC [14–19].”
BackgroundIntestinal transport and metabolism of bile acids
Dawson, P. A., & Karpen, S. J. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r054114 · Cited by 598 · cited 2×
“Evidence indicates that bile acid glucuronidation is an increasingly important and active process under cholestatic conditions [22,23].”
BackgroundA metabolic pathway for bile acid dehydroxylation by the gut microbiome
Funabashi, M., Grove, T. L., Wang, M., Varma, Y., McFadden, M. E., Brown, L. C., Guo, C., Higginbottom, S., Almo, S. C., & Fischbach, M. A. (2020) · Nature · doi:10.1038/s41586-020-2396-4 · Cited by 590 · cited 1×
“Next, CA and CDCA, produced in the liver, are converted to secondary bile acids, e.g., deoxycholic acid (DCA) and lithocholic acid (LCA), by bacterial 7 α -dehydroxylating enzymes present in the intestinal microflora [29].”
BackgroundGlobal chemical effects of the microbiome include new bile-acid conjugations
Quinn, R. A., Melnik, A. V., Vrbanac, A., Fu, T., Patras, K. A., Christy, M. P., Bodai, Z., Belda-Ferre, P., Tripathi, A., Chung, L. K., et al. (2020) · Nature · doi:10.1038/s41586-020-2047-9 · Cited by 579 · cited 1×
“Newer evidence indicates that organisms within the human microbiome can synthesize unique amino acid amide conjugates to CA, namely phenylalanine, tyrosine, or leucine, to produce microbially conjugated bile acids, including phenylalanocholic acid, tyrosocholic acid, and leucocholic acid [35].”
BackgroundUDP-glucuronosyltransferases and clinical drug-drug interactions
KIANG, T., ENSOM, M., & CHANG, T. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.013 · Cited by 552 · cited 1×
“In humans, hydrophobic molecules, e.g., bile acids, undergo glucuronidation catalyzed by UGT enzymes [38].”
BackgroundSher, T., Yi, H. F., McBride, O. W., & Gonzalez, F. J. (1993) · Biochemistry · doi:10.1021/bi00072a015 · Cited by 519
Schmidt, A. (1992) · Molecular Endocrinology · doi:10.1210/me.6.10.1634 · Cited by 477 · cited 1×
“The peroxisome proliferator-activated receptor (PPAR), a ligand-activated transcription factor of the nuclear receptor superfamily, includes three distinct isoforms ( α , β / δ , and γ ) that are encoded by different genes [6–8].”
BackgroundKuiper, E. M. M., Hansen, B. E., de Vries, R. A., den Ouden–Muller, J. W., van Ditzhuijsen, T. J. M., Haagsma, E. B., Houben, M. H. M. G., Witteman, B. J. M., van Erpecum, K. J., & van Buuren, H. R. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.003 · Cited by 460 · cited 1×
“Ursodeoxycholic acid (UDCA) is the first line of treatment for patients with PBC; however, ~40% of patients have an incomplete response [3] and it has not been shown to improve survival in PSC [4].”
BackgroundGreene, M. E., Blumberg, B., McBride, O. W., Yi, H., Kronquist, K. E., Kwan, K. W., Hsieh, L., Greene, G. L., & Nimer, S. D. (1995) · Europe PMC (PubMed Central) · Cited by 399
Schoonjans, K., Watanabe, M., Suzuki, H., Mahfoudi, A., Krey, G., Wahli, W., Grimaldi, P., Staels, B., Yamamoto, T., & Auwerx, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.33.19269 · Cited by 395 · cited 1×
“PPAR α is expressed in tissues that undergo high fatty acid catabolism, e.g., the liver, kidney, intestine, and brown adipose tissue [11], where it also stimulates fatty acid catabolism [12] and attenuates inflammatory responses [13].”
BackgroundInduction of bilirubin clearance by the constitutive androstane receptor (CAR)
Huang, W., Zhang, J., Chua, S. S., Qatanani, M., Han, Y., Granata, R., & Moore, D. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630614100 · Cited by 390 · cited 1×
“UGT1A1 : UGT1A1 (along with UGT1A4) is responsible for the glucuronidation of bilirubin [58–61].”
BackgroundPPARα: Energy Combustion, Hypolipidemia, Inflammation and Cancer
Pyper, S. R., Viswakarma, N., Yu, S., & Reddy, J. K. (2010) · Nuclear Receptor Signaling · doi:10.1621/nrs.08002 · Cited by 379 · cited 1×
“PPAR α is expressed in tissues that undergo high fatty acid catabolism, e.g., the liver, kidney, intestine, and brown adipose tissue [11], where it also stimulates fatty acid catabolism [12] and attenuates inflammatory responses [13].”
BackgroundCali, J. J., & Russell, D. W. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)89517-9 · Cited by 368
Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317 · cited 1×
“In particular, PPAR α downregulates bile acid synthesis by inhibiting CYP enzymes, e.g., CYP7A1 and CYP27A1 [50], making it a desirable target for the pharmacological that PPAR promoter HepG2 cells cyp27a1 expression and reduce their activity in rodents [53].”
BackgroundSelf-citationUp to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis
Chiang, J. Y. L., & Ferrell, J. M. (2020) · Liver Research · doi:10.1016/j.livres.2020.05.001 · Cited by 294 · cited 1×
“Next, C4, a surrogate serum marker of bile acid synthesis [25], can be converted to the primary bile acid cholic acid (CA) by CYP8B1 or to chenodeoxycholic acid (CDCA) [26].”
BackgroundPathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287 · cited 1×
“Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are cholestatic liver diseases characterized by the accumulation of bile acids in the liver [2].”
BackgroundInherited disorders of bilirubin metabolism
Bosma, P. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00359-8 · Cited by 279
Bile Acid Metabolism and Signaling
Chiang, J. Y. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00517.x · Cited by 279 · cited 1×
“In a healthy adult, approximately 0.2–0.6 g of bile acids are synthesized daily from cholesterol in the liver, and the daily net turnover of bile acids is ~3 g, or ~5% of the total bile acid pool [24].”
BackgroundInfluentialRitter, J. K., Crawford, J. M., & Owens, I. S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35280-8 · Cited by 256
Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis
Xie, G., Wang, X., Huang, F., Zhao, A., Chen, W., Yan, J., Zhang, Y., Lei, S., Ge, K., Zheng, X., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30219 · Cited by 252 · cited 1×
“However, these secondary bile acids are more hydrophobic, e.g., cytotoxic, and elevated levels of these hydrophobic bile acids have been associated with liver carcinogenesis [30] and hepato-toxicity [31] in mice.”
BackgroundBile acids and intestinal microbiota in autoimmune cholestatic liver diseases
Li, Y., Tang, R., Leung, P. S. C., Gershwin, M. E., & Ma, X. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.002 · Cited by 247 · cited 1×
“Under healthy conditions, bile acid synthesis is essential to maintain lipid and cholesterol homeostasis; however, when the process is dysregulated, the accumulation of bile acids in the liver can lead to oxidative stress and apoptosis and the development of cholestatic liver diseases [36].”
BackgroundPost, S. M., Duez, H., Gervois, P. P., Staels, B., Kuipers, F., & Princen, H. M. G. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1101.098228 · Cited by 217 · cited 1×
“In particular, PPAR α downregulates bile acid synthesis by inhibiting CYP enzymes, e.g., CYP7A1 and CYP27A1 [50], making it a desirable target for the pharmacological that PPAR promoter HepG2 cells cyp27a1 expression and reduce their activity in rodents [53].”
BackgroundGlucuronidation: driving factors and their impact on glucuronide disposition
Yang, G., Ge, S., Singh, R., Basu, S., Shatzer, K., Zen, M., Liu, J., Tu, Y., Zhang, C., Wei, J., et al. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1293682 · Cited by 215 · cited 1×
“Glucuronidation is one of the main mechanisms of elimination, e.g., a detoxification process, of endogenous substances and xenobiotics in humans [20].”
BackgroundHonda, A., Ikegami, T., Nakamuta, M., Miyazaki, T., Iwamoto, J., Hirayama, T., Saito, Y., Takikawa, H., Imawari, M., & Matsuzaki, Y. (2013) · Hepatology · doi:10.1002/hep.26018 · Cited by 210 · cited 1×
“Similarly, the pan-PPAR agonist bezafibrate decreased the mRNA expression of CYP7A1 and CYP27A1 in HepaRG cells [16] and decreased hepatic CYP7A1 activity by nearly 60% in patients with gallstones undergoing cholecystectomy [77].”
BackgroundSchattenberg, J. M., Pares, A., Kowdley, K. V., Heneghan, M. A., Caldwell, S., Pratt, D., Bonder, A., Hirschfield, G. M., Levy, C., Vierling, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.013 · Cited by 191 · cited 1×
“Clinical trials of elafibranor [78] and seladelpar [79,80] have also shown decreases in circulating levels of C4, along with significant decreases in total bile acids from seladelpar treatment [81].”
BackgroundLevy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186
Marrapodi, M., & Chiang, J. Y. L. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32398-1 · Cited by 183
Lindström, L., Hultcrantz, R., Boberg, K. M., Friis–Liby, I., & Bergquist, A. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.12.032 · Cited by 180 · cited 1×
“Ursodeoxycholic acid (UDCA) is the first line of treatment for patients with PBC; however, ~40% of patients have an incomplete response [3] and it has not been shown to improve survival in PSC [4].”
BackgroundEnterohepatic transport of bile salts and genetics of cholestasis
Pauli-Magnus, C., Stieger, B., Meier, Y., Kullak-Ublick, G. A., & Meier, P. J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.03.017 · Cited by 175 · cited 1×
“In general, glucuronidation enhances the negative charge of the bile acid, thereby facilitating its export out of the liver and into systemic circulation for subsequent renal excretion [46], i.e., bile acid detoxification.”
BackgroundSong, P., Zhang, Y., & Klaassen, C. D. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr177 · Cited by 154 · cited 1×
“However, these secondary bile acids are more hydrophobic, e.g., cytotoxic, and elevated levels of these hydrophobic bile acids have been associated with liver carcinogenesis [30] and hepato-toxicity [31] in mice.”
BackgroundEffect of different bile acids on the intestine through enterohepatic circulation based on FXR
Xiang, J., Zhang, Z., Xie, H., Zhang, C., Bai, Y., Cao, H., Che, Q., Guo, J., & Su, Z. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1949095 · Cited by 149 · cited 1×
“Approximately 95% of the bile acids in the intestine are reabsorbed and transported back to the liver via the portal vein [32].”
BackgroundDifferential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7
Gall, W. E., Zawada, G., Mojarrabi, B., Tephly, T. R., Green, M. D., Coffman, B. L., Mackenzie, P. I., & Radominska-p, A. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00088-6 · Cited by 145 · cited 2×
“G, e.g., CA, CDCA-, DCA-, LCA-, HCA-, and HDCA-24G [21,41,49].”
BackgroundBarbier, O., Duran-Sandoval, D., Pineda-Torra, I., Kosykh, V., Fruchart, J.-C., & Staels, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305361200 · Cited by 142 · cited 7×
“UGT2B7 : UGT2B7 contributes to the formation of -3 and -6 bile acid glucuronides [39, 42] and has recently been reported as one of the most relevant UGT enzymes in bile acid glucuronidation due to its production of HDCA-G in human recombinant enzyme and human liver microsomes [70].”
BackgroundInfluentialSelf-citationNovel pathways of bile acid metabolism involving CYP3A4
Bodin, K., Lindbom, U., & Diczfalusy, U. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2004.11.003 · Cited by 141 · cited 1×
“Once reabsorbed, the remaining secondary bile acids can undergo hydroxylation at the 6-hydroxyl steroid nucleus by CYP3A4 to hyodeoxycholic acid (HDCA) and hyocholic acid (HCA) [33].”
BackgroundSenekeo‐Effenberger, K., Chen, S., Brace‐Sinnokrak, E., Bonzo, J. A., Yueh, M., Argikar, U. A., Kaeding, J., Trottier, J., Remmel, R. P., Ritter, J. K., et al. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013243 · Cited by 135 · cited 6×
“…serum bile acid glucuronides by ~2-fold vs. UDCA monotherapy and ~6-fold compared to healthy controls [18]. directly activates several UGT enzymes [42,55] involved in bile acid and bilirubin glucuronidation to promote the production of and enhance the urinary excretion of glucuronide conjugates.”
BackgroundInfluentialSelf-citationAlmé, B., & Sjövall, J. (1980) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(80)90164-8 · Cited by 132
Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000395 · Cited by 127 · cited 1×
“Clinical trials of elafibranor [78] and seladelpar [79,80] have also shown decreases in circulating levels of C4, along with significant decreases in total bile acids from seladelpar treatment [81].”
BackgroundBoyer, J. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00519.x · Cited by 124 · cited 1×
“Bile acids are critical to maintaining cholesterol and metabolic homeostasis [1].”
BackgroundSelf-citationHuman UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver
Trottier, J., Verreault, M., Grepper, S., Monté, D., Bélanger, J., Kaeding, J., Caron, P., Inaba, T. T., & Barbier, O. (2006) · Hepatology · doi:10.1002/hep.21362 · Cited by 120 · cited 3×
“Fenofibrate and Wy-14,643 stimulate UGT1A3 expression [39], and treatment with Wy-14,643 increases CDCA-24G formation in human hepatocytes and HepG2 cells [49].”
BackgroundSelf-citationCholesterol 25-hydroxylation activity of CYP3A
Honda, A., Miyazaki, T., Ikegami, T., Iwamoto, J., Maeda, T., Hirayama, T., Saito, Y., Teramoto, T., & Matsuzaki, Y. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014084 · Cited by 114 · cited 1×
“In the alternative pathway, cholesterol is converted to 25(R)-26-hydroxycholesterol or 25-hydroxycholesterol by CYP27A1 [27] or CYP3A4 [28], respectively, which undergo hydroxylation at the 7 α -hydroxy steroid nucleus by CYP7B1 for the subsequent synthesis of CA and CDCA.”
BackgroundFang, H.-L., Strom, S. C., Cai, H., Falany, C. N., Kocarek, T. A., & Runge‐Morris, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.005389 · Cited by 112 · cited 1×
“While not covered in this review, it is important to mention that other bile acid detoxification pathways, e.g., sulfonation, also promote the detoxification of the bile acid pool through PPAR-mediated mechanisms [82].”
BackgroundShelby, M. K., & Klaassen, C. D. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010397 · Cited by 104 · cited 1×
“Rats treated with PPAR α agonists showed increased hepatic UGT1A1 mRNA [64], and PPAR α activation by clofibrate in primary rat hepatocytes increased UGT1A1 protein expression [64,65].”
BackgroundSerum Concentrations of 7α–Hydroxy–4–Cholesten–3–One Reflect Bile Acid Synthesis in Humans
Sauter, G., Berr, F., Beuers, U., Fischer, S., & Paumgartner, G. (1996) · Hepatology · doi:10.1002/hep.510240121 · Cited by 95
Lipid-activated transcription factors control bile acid glucuronidation
Barbier, O., Trottier, J., Kaeding, J., Caron, P., & Verreault, M. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0001-5 · Cited by 94 · cited 4×
“G, e.g., CA, CDCA-, DCA-, LCA-, HCA-, and HDCA-24G [21,41,49].”
BackgroundInfluentialSelf-citationPillot, T., Ouzzine, M., Fournel‐Gigleux, S., Lafaurie, C., Radominska-p, A., Burchell, B., Siest, G., & Magdalou, J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74437-8 · Cited by 88 · cited 1×
“UGT2B4: UGT2B4 (and UGT2B7) are responsible for the formation of HDCA-6G [42,69] and HCA-6G [21].”
BackgroundBowlus, C. L., Galambos, M. R., Aspinall, R. J., Hirschfield, G. M., Jones, D. E. J., Dörffel, Y., Gordon, S. C., Harrison, S. A., Kremer, A. E., Mayo, M. J., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.033 · Cited by 80 · cited 1×
“Clinical trials of elafibranor [78] and seladelpar [79,80] have also shown decreases in circulating levels of C4, along with significant decreases in total bile acids from seladelpar treatment [81].”
BackgroundLemoinne, S., Pares, A., Reig, A., Ben Belkacem, K., Kemgang Fankem, A. D., Gaouar, F., Poupon, R., Housset, C., Corpechot, C., & Chazouillères, O. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.06.009 · Cited by 74
Sneitz, N., Court, M. H., Zhang, X., Laajanen, K., Yee, K. K., Dalton, P., Ding, X., & Finel, M. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283330767 · Cited by 68 · cited 1×
“Although additional UGT isoforms including 2A1 and 2A2 have been identified as bile acid-glucuronidating enzymes [43], their expression in the human liver has not been observed [44,45].”
BackgroundStåhlberg, D., Reihnér, E., Rudling, M., Berglund, L., Einarsson, K., & Angelin, B. (1995) · Hepatology · doi:10.1002/hep.1840210421 · Cited by 67 · cited 1×
“Similarly, the pan-PPAR agonist bezafibrate decreased the mRNA expression of CYP7A1 and CYP27A1 in HepaRG cells [16] and decreased hepatic CYP7A1 activity by nearly 60% in patients with gallstones undergoing cholecystectomy [77].”
BackgroundTrottier, J., Caron, P., Straka, R. J., & Barbier, O. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.124 · Cited by 67 · cited 1×
“Regarding bile acid levels, fenofibrate significantly reduced serum levels of CDCA and the secondary bile acids DCA, LCA, and HDCA, in non-cholestatic adult volunteers [54].”
BackgroundSelf-citationKouno, T., Liu, X., Zhao, H., Kisseleva, T., Cable, E. E., & Schnabl, B. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102056 · Cited by 66 · cited 2×
“In studies with primary human and mouse hepatocytes, treatment with seladelpar significantly decreased CYP7A1 mRNA expression, and cyp7a1 mRNA and protein expression, respectively [72].”
BackgroundSeladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis
Kremer, A. E., Mayo, M. J., Hirschfield, G. M., Levy, C., Bowlus, C. L., Jones, D. E., Johnson, J. D., McWherter, C. A., & Choi, Y.-J. (2024) · Hepatology · doi:10.1097/hep.0000000000000728 · Cited by 61 · cited 1×
“Clinical trials of elafibranor [78] and seladelpar [79,80] have also shown decreases in circulating levels of C4, along with significant decreases in total bile acids from seladelpar treatment [81].”
BackgroundCoordinate Regulation of Hepatic Bile Acid Oxidation and Conjugation by Nuclear Receptors
Trottier, J., Milkiewicz, P., Kaeding, J., Verreault, M., & Barbier, O. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060020t · Cited by 58 · cited 2×
“Evidence indicates that bile acid glucuronidation is an increasingly important and active process under cholestatic conditions [22,23].”
BackgroundSelf-citationBock, K. W. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.009 · Cited by 57 · cited 1×
“UGT1A1 : UGT1A1 (along with UGT1A4) is responsible for the glucuronidation of bilirubin [58–61].”
BackgroundGhonem, N. S., Auclair, A. M., Hemme, C. L., Gallucci, G. M., de la Rosa Rodriguez, R., Boyer, J. L., & Assis, D. N. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1930 · Cited by 57 · cited 5×
“Likewise, Ghonem et al. [14] showed that patients with In addition to regulating CYP enzymes involved in bile acid synthesis, PPAR α directly activates several UGT enzymes [42,55] involved in bile acid and bilirubin glucuronidation to promote the production of and enhance the urinary excretion of…”
BackgroundInfluentialSelf-citationPerreault, M., Gauthier-Landry, L., Trottier, J., Verreault, M., Caron, P., Finel, M., & Barbier, O. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052613 · Cited by 54 · cited 1×
“Although additional UGT isoforms including 2A1 and 2A2 have been identified as bile acid-glucuronidating enzymes [43], their expression in the human liver has not been observed [44,45].”
BackgroundSelf-citationSerum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans
Sauter, G. (1996) · Hepatology · doi:10.1053/jhep.1996.v24.pm0008707250 · Cited by 54 · cited 1×
“Next, C4, a surrogate serum marker of bile acid synthesis [25], can be converted to the primary bile acid cholic acid (CA) by CYP8B1 or to chenodeoxycholic acid (CDCA) [26].”
BackgroundJemnitz, K., Veres, Z., Monostory, K., & Vereczkey, L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15000-3 · Cited by 51 · cited 1×
“Rats treated with PPAR α agonists showed increased hepatic UGT1A1 mRNA [64], and PPAR α activation by clofibrate in primary rat hepatocytes increased UGT1A1 protein expression [64,65].”
BackgroundPerreault, M., Białek, A., Trottier, J., Verreault, M., Caron, P., Milkiewicz, P., & Barbier, O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080994 · Cited by 49 · cited 2×
“…while receiving UDCA UDCA monotherapy and ~6-fold For example, HepG2 cells treated with CDCA-3G and DCA-3G undergo apoptosis and necrosis [56], and LCA-3G induces cholestasis in rats [57], suggesting that an increase in total serum bile acid glucuronide levels is not an adequate…”
BackgroundSelf-citationTrottier, J., Perreault, M., Rudkowska, I., Levy, C., Dallaire-Theroux, A., Verreault, M., Caron, P., Staels, B., Vohl, M.-C., Straka, R. J., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.122 · Cited by 48 · cited 10×
“UGT2B7 : UGT2B7 contributes to the formation of -3 and -6 bile acid glucuronides [39, 42] and has recently been reported as one of the most relevant UGT enzymes in bile acid glucuronidation due to its production of HDCA-G in human recombinant enzyme and human liver microsomes [70].”
BackgroundInfluentialSelf-citationGallucci, G. M., Alsuwayt, B., Auclair, A. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2022) · Inflammation · doi:10.1007/s10753-022-01713-1 · Cited by 46
Self-citationHyperbilirubinemia and cholestasis
Berk, P. D., & Javitt, N. B. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90061-x · Cited by 43 · cited 1×
“Bilirubin glucuronidation is the rate-limiting step in bilirubin excretion [62], and hyperbilirubinemia is a characteristic found in individuals with cholestasis [63].”
BackgroundPerakakis, N., Stefanakis, K., Feigh, M., Veidal, S. S., & Mantzoros, C. S. (2021) · Liver International · doi:10.1111/liv.14888 · Cited by 42 · cited 1×
“In addition, elafibranor treatment reduced cholate, chenodeoxycholate, and ursodeoxycholate levels in a diet-induced obese mouse model of non-alcoholic fatty liver disease [75].”
BackgroundBarbier, O., & Bélanger, A. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00235-8 · Cited by 41 · cited 1×
“Glucuronidation is an important phase II metabolic pathway involved in the detoxification of numerous endogenous compounds including bile acids, steroids, and xenobiotics [23,37].”
BackgroundSelf-citationBushey, R. T., Chen, G., Blevins‐Primeau, A. S., Krzeminski, J., Amin, S., & Lazarus, P. J. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328341db05 · Cited by 41 · cited 1×
“Although additional UGT isoforms including 2A1 and 2A2 have been identified as bile acid-glucuronidating enzymes [43], their expression in the human liver has not been observed [44,45].”
BackgroundNovel insights into bile acid detoxification via CYP, UGT and SULT enzymes
Kastrinou‐Lampou, V., Poller, B., Huth, F., Fischer, A., Kullak-Ublick, G. A., Arand, M., Schadt, H. S., & Camenisch, G. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105533 · Cited by 41 · cited 1×
“UGT2B7 : UGT2B7 contributes to the formation of -3 and -6 bile acid glucuronides [39, 42] and has recently been reported as one of the most relevant UGT enzymes in bile acid glucuronidation due to its production of HDCA-G in human recombinant enzyme and human liver microsomes [70].”
BackgroundGbaguidi, G. F. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh260 · Cited by 39
Briand, F., Maupoint, J., Brousseau, E., Breyner, N., Bouchet, M., Costard, C., Leste-Lasserre, T., Petitjean, M., Chen, L., Chabrat, A., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154707 · Cited by 36 · cited 1×
“Similarly, elafibranor significantly decreased hepatic cyp7a1 expression and inflammatory markers in a hamster model of NASH and heart failure [74].”
BackgroundCaron, P., Trottier, J., Verreault, M., Bélanger, J., Kaeding, J., & Barbier, O. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060021l · Cited by 29 · cited 2×
“Specifically, glucuronidation involves the transfer of the glucuronosyl group from uridine 5-diphosphoglucuronic acid (UDPGA) to acceptor substrates, including the 3/6-hydroxyl or 24-carboxyl bile acid steroid nucleus, to produce corresponding ether -3/6G or acyl -24G [47–49].”
BackgroundSelf-citationChen, S., & Tukey, R. H. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083212 · Cited by 29 · cited 1×
“Bilirubin glucuronidation is the rate-limiting step in bilirubin excretion [62], and hyperbilirubinemia is a characteristic found in individuals with cholestasis [63].”
BackgroundGallucci, G. M., Trottier, J., Hemme, C., Assis, D. N., Boyer, J. L., Barbier, O., & Ghonem, N. S. (2021) · Hepatology Communications · doi:10.1002/hep4.1787 · Cited by 26 · cited 8×
“In primary human hepatocytes, PPAR α activation by fenofibrate [18] and Wy-14,643 upregulates UGT2B4 mRNA expression [39].”
BackgroundInfluentialSelf-citationPerreault, M., Wunsch, E., Bialek, A. P., Trottier, J., Verreault, M., Caron, P., Poirier, G. G., Milkiewicz, P., & Barbier, O. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/8096314 · Cited by 24 · cited 3×
“Hyocholic acid (HCA)-6G and hyodeoxy-cholic acid (HDCA)-6G are among the most abundant bile acid glucuronides found in the serum of non-cholestatic adults [39], patients with PBC and PSC [18], and in the urine of adults with biliary obstruction, pre-and post-biliary stenting [48].”
BackgroundSelf-citationPPARα: A Master Regulator of Bilirubin Homeostasis
Bigo, C., Kaeding, J., Husseini, D. E., Rudkowska, I., Verreault, M., Vohl, M., & Barbier, O. (2014) · PPAR Research · doi:10.1155/2014/747014 · Cited by 21 · cited 1×
“We [18] and others [55,67] have shown that fenofibrate and Wy-14,643 upregulate UGT1A1 mRNA levels in both HepG2 cells and primary human hepatocytes.”
BackgroundSelf-citationLithocholate-3-O-glucuronide-induced cholestasis
Takikawa, H., Minagawa, K., Sano, N., & Yamanaka, M. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01308618 · Cited by 19 · cited 1×
“…UDCA UDCA monotherapy and ~6-fold For example, HepG2 cells treated with CDCA-3G and DCA-3G undergo apoptosis and necrosis [56], and LCA-3G induces cholestasis in rats [57], suggesting that an increase in total serum bile acid glucuronide levels is not an adequate indicator of therapeutic response.”
BackgroundWhy bile acid glucuronidation is a minor pathway for conjugation of endogenous bile acids in man†
Hofmann, A. F. (2007) · Hepatology · doi:10.1002/hep.21576 · Cited by 18 · cited 1×
“…acid acyl glucuronides detected in human serum [18,39] was the result of preferential glycine-and taurine-conjugation to the C 24 carboxyl group [68], or as a result of degradation due to temperature and pH instability [47], in which case, serum levels of these bile acid acyl glucuronides may…”
BackgroundChoi, Y., Johnson, J. D., Lee, J.-J., Song, J., Matthews, M. D., Hellerstein, M. K., & McWherter, C. A. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00158.2023 · Cited by 17 · cited 1×
“Furthermore, seladelpar treatment decreased the hepatic mRNA expression of cyp7a1 and plasma levels of C4 in wild-type mice [72] and hepatic cyp7a1 gene expression in diet-induced obese non-alcoholic steatohepatitis (NASH) mice [73].”
BackgroundWeismüller, T. J., Zhou, T., Kalthoff, S., Lenzen, H., Manns, M. P., & Strassburg, C. P. (2020) · Liver International · doi:10.1111/liv.14487 · Cited by 8 · cited 1×
“…with the impact of bile acid and bile acid glucuronide composition, single-nucleotide polymorphisms (SNPs) in UGT1A3 and 2B genes have been shown to alter the production of bile acid glucuronides in healthy volunteers [39], whereas other SNPs, e.g., UGT1A1, influence patient outcomes in PSC [71].”
BackgroundWang, C., Peng, F., Zhong, B., Shi, Y., Wang, X., Jin, X., & Niu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732478 · Cited by 5 · cited 1×
“Interestingly, treatment with MBT1805, a pan-PPAR agonist, significantly reduced the expression of cyp27A1 and elevated levels of taurine-and glycine-conjugated bile acids in an ANIT-induced cholestatic mouse model [76].”
BackgroundHeydel, J., Garnier, P. E., Fauré, P., & Artur, Y. (2012) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-012-0091-z · Cited by 3 · cited 1×
“These effects were observed in rats treated with ciprofibrate, as PPAR α activation-induced bilirubin glucuronidation activity [66].”
Background
Cited by
Levy, C., Abouda, G. F., Bilir, B. M., Bonder, A., Bowlus, C. L., Campos‐Varela, I., Cazzagon, N., Chandok, N., Cheent, K. S., Cortez‐Pinto, H., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.04.025 · Cited by 37
Trauner, M., Karpen, S. J., & Dawson, P. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001438 · Cited by 32
“…BA synthesis (PPAR alpha and delta), increasing BA glucuronidation (PPAR alpha), and increasing canalicular BA and PL excretion (PPAR alpha), [230,231] PPAR agents ’ principal actions appear to be more anti-fibrotic and anti-inflammatory through non-parenchymal cells, properties known for many…”
Ghallab, A., Mandorfer, M., Stirnimann, G., Geyer, J., Lindström, E., Luedde, T., der Merwe, V., Rashidi‐Alavijeh, J., Schmidt, H., Karpen, S. J., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.05.009 · Cited by 26
“28 Like the liver, 29 the kidney also possesses bile acid glucuronidation capacity 30 and may directly metabolise bile acids to promote their urinary excretion.”
Wang, X., Klaassen, C. D., Chen, X., & Zhang, Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100073 · Cited by 18
Bashiri, K., Mattar, M. C., Meighani, A., & Mason, A. L. (2025) · Intestinal Research · doi:10.5217/ir.2025.00090 · Cited by 21
“Liver Diseases to CD The successful application of PPAR agonists in cholestatic liver diseases provides a compelling rationale for exploring their use in CD.”
Influential
Metadata
- Authors
- Gallucci, G. M., Hayes, C. M., Boyer, J. L., Barbier, O., Assis, D. N., & Ghonem, N. S.
- Affiliations
- University of Rhode Island (US)
- Yale University (US)
- Université Laval (CA)
- Corresponding author
- Ghonem, Nisanne S.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2024-08-01
- Volume
- 13
- Issue
- 15
- Pages
- 1296
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC11312002
- OpenAlex
- W4401218243
- Cited by
- 40
- References
- 84
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 1
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- peroxisome proliferator-activated receptors, cholestatic liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, PPARα agonist, fenofibrate, elafibranor, ursodeoxycholic acid, obeticholic acid, UGT enzymes, CYP enzymes, bile acid metabolism, nuclear receptors, adjunctive therapy
- MeSH terms
- Animals, Bile Acids and Salts, Cholestasis, Humans, Liver Cirrhosis, Biliary, Cholangitis, Sclerosing, Peroxisome Proliferator-Activated Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.